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Abstract
Background: Hepatocyte growth factor (HGF) has been demonstrated to stimulate osteoblast proliferation and participated
bone remodeling. Osteopontin (OPN) is a secreted phosphoglycoprotein that belongs to the SIBLING family and is present
during bone mineralization. However, the effects of HGF on OPN expression in human osteoblasts are large unknown.
Methodology/Principal Findings: Here we found that HGF induced OPN expression in human osteoblasts dose-
dependently. HGF-mediated OPN production was attenuated by c-Met inhibitor and siRNA. Pretreatment of osteoblasts
with PI3K inhibitor (Ly294002), Akt inhibitor, c-Src inhibitor (PP2), or AP-1 inhibitor (curcumin) blocked the potentiating
action of HGF. Stimulation of osteoblasts with HGF enhanced PI3K, Akt, and c-Src activation. In addition, incubation of cells
with HGF also increased c-Jun phosphorylation, AP-1-luciferase activity, and c-Jun binding to the AP-1 element on the OPN
promoter. HGF-mediated AP-1-luciferase activity and c-Jun binding to the AP-1 element was reduced by c-Met inhibitor,
Ly294002, Akt inhibitor, and PP2.
Conclusions/Significance: Our results suggest that the interaction between HGF and c-Met increases OPN expression in
human osteoblasts via the PI3K, Akt, c-Src, c-Jun, and AP-1 signaling pathway.
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Introduction
Bone is a complex tissue composed of several cell types which
are continuously undergoing a process of renewal and repair
termed ‘‘bone remodeling’’. The two major cell types responsible
for bone remodeling are osteoclasts, which resorb bone, and
osteoblasts, which form new bone. Bone remodeling is regulated
by several systemic hormones (e.g., parathyroid hormone, 1, 25-
dihydroxybitamin D3, sex hormones, and calcitonin), and local
factors (e.g., nitric oxide, prostaglandins, growth factors, and
cytokines) [1]. When resorption and formation of bone are not
coordinated and bone breakdown overrides bone building,
osteoporosis results [2]. Since new bone formation is primarily
a function of the osteoblast, agents that act by either increasing the
proliferation of cells of the osteoblastic lineage or inducing
differentiation of the osteoblasts can enhance bone formation
[3,4].
Multiple anabolic signaling pathways are positively involved in
controlling bone formation, such as bone morphogenetic proteins
and osteopontin (OPN). OPN is a secreted phosphoglycoprotein
that belongs to the SIBLING family and is present in various
mineralized and soft tissues as well as in body fluids. OPN, a major
member of the noncollagenous extracellular matrix secreted by
osteoblasts and a cytokine involved in proliferation, apoptosis, and
inflammatory signaling, has been implicated in bone remodeling
[5]. It contains an RGDS motif, exhibits high affinity to calcium,
and is produced by osteoblasts and osteoclasts. Despite the absence
of a clear phenotype in OPN knockout mice, recent studies have
implicated OPN in diverse biological processes, including de-
velopment, wound healing, immunological responses, bone re-
sorption, and calcification [6]. In addition, OPN-deficient mice
also show reduced osteoblastic bone formation [7]. However,
which mechanisms are regulated OPN expression in osteoblasts
needs to be well elucidated.
Hepatocyte growth factor (HGF) was identified in the early
1980s [8,9] and was subsequently determined to be a hetero-
dimeric molecule composed of an alpha and beta chain [10].
The importance of HGF in organ development is demonstrated
by HGF null mutation mice, which exhibit embryonic lethality
[11]. HGF exhibits strong angiogenic properties through its
ability to induce expression of vascular endothelial growth
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properties of its own [12]. Osteoblasts and osteoclasts express
c-Met, the receptor for HGF and produce HGF [13]. HGF has
been demonstrated to stimulate both osteoblast proliferation and
osteoclast chemotactic migration [13]. In combination with
vitamin D, HGF promotes osteoblast differentiation of vertebral
bone marrow cells [14]. We hypothesized that HGF controls
OPN expression in osteoblasts. This study was designed to test
this hypothesis and also determine the precise signaling
pathway.
Previous studies have shown that HGF modulates osteoblastic
bone formation [13,14]. HGF-mediated bone formation may
involve activation of c-Met receptor. However, the effect of HGF
on OPN (an osteoblastic formation gene) expression in human
osteoblasts is mostly unknown. In this study, we found that HGF
induces OPN expression in human osteoblasts. In addition, c-Met
receptor, PI3K, Akt, c-Src, and AP-1 signaling pathways may be
involved in the increase of OPN expression by HGF.
Materials and Methods
Materials
Anti-mouse and anti-rabbit IgG-conjugated horseradish per-
oxidase, rabbit polyclonal antibodies specific for b-actin, p-p85,
p85, p-Akt, Akt, c-Src, p-c-Jun, c-Jun, and the small interfering
RNAs (siRNAs) against c-Met, p85, Akt, c-Src, c-Jun, and
a control for experiments using targeted siRNA transfection
(each consists of a scrambled sequence that does not lead to
specific degradation of any known cellular mRNA) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Rabbit polyclonal antibodies specific for c-Src phosphorylated at
Tyr
416 was purchased from Cell Signaling and Neuroscience
(Danvers, MA). Mouse monoclonal antibodies specific for OPN,
c-Met, and OPN enzyme immunoassay kit were purchased from
R&D Systems (Minneapolis, MN, USA). Recombinant human
HGF was purchased from PeproTech (Rocky Hill, NJ). The
AP-1 luciferase plasmid was purchased from Stratagene (La
Figure 1. HGF increases OPN expression through c-Met receptor. (A&B) Cells were incubated with HGF for 24 h, and OPN mRNA was
examined by qPCR (n=4). (C-E) Osteoblasts were incubated with HGF for 24 h, and OPN protein was examined by ELISA and Western blotting (n=4).
(F-I) Cells were pretreated for 30 min with c-Met inhibitor or transfected with c-Met siRNA for 24 h followed by stimulation with HGF for 24 h, and
OPN expression was examined by qPCR and ELISA (n=4). *: p,0.05 as compared with basal level (A-D) or HGF-treated group (F-I).
doi:10.1371/journal.pone.0038378.g001
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residues 479 to 513 of p85) and Akt (Akt K179A) dominant-
negative mutants were gifts from Dr. W.M. Fu (National
Taiwan University, Taipei, Taiwan). The c-Src dominant
negative mutant was a gift from Dr. S. Parsons (University of
Virginia Health System, Charlottesville, VA). The pSV-b-
galactosidase vector and luciferase assay kit were purchased
from Promega (Madison, WI). All other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO).
Cell Culture
The MG-63 and hFOB cell lines were purchased from
American Type Culture Collection (ATCC; Rockville, MD).
The human osteoblast-like cell line MG-63 was cultured in MEM
supplemented with 10% FBS and antibiotics (100 U/ml of
penicillin G and 100 mg/ml of streptomycin). The conditionally
immortalized human fetal osteoblastic cell line, hFOB, was
maintained in a 1:1 mixture of phenol-free DMEM/Ham’s F12
medium (GIBCO-BRL; Gaithersburg, MD) containing 10% FBS
supplemented with geneticin (300 mg/ml) and antibiotics at
Figure 2. PI3K is involved in HGF-induced OPN expression. Cells were pretreated for 30 min with Ly294002 or transfected with p85 mutant
and siRNA followed by stimulation with HGF for 24 h. Media and total RNA were collected, and the expression of OPN was analyzed with qPCR and
ELISA (n=4) (A-D). Primary osteoblasts were incubated with HGF for indicated time intervals, and p85 phosphorylation was examined by Western
blotting (E). Primary osteoblasts were pretreated with c-Met inhibitor for 30 min or transfected with c-Met siRNA for 24 h followed by stimulation
with HGF for 30 min, and p85 phosphorylation was determined by Western blotting (n=5) (F). *: p,0.05 as compared with HGF-treated group.
doi:10.1371/journal.pone.0038378.g002
HGF Induces OPN Expression
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T antigen. All experiments with hFOB cells were carried out at the
permissive temperature of 33.5uC.
Primary human osteoblasts were isolated from bone chips of
ten 40–60-year-old donors who were generally healthy with no
other bone disorders than hip dysplasia for which they received
hip arthroplasty at China Medical University Hospital. The
protocol for this study was approved by the Institutional Review
Board at China Medical University Hospital and the informed
consent was obtained from each donor. The osteoblasts were
cultured in DMEM containing 100 mg/ml of ascorbic acid,
non-essential amino acids, penicillin/streptomycin and 10%
Figure 3. Akt is involved HGF-induced OPN expression. Cells were pretreated for 30 min with Akt inhibitor or transfected with Akt mutant and
siRNA followed by stimulation with HGF for 24 h. Media and total RNA were collected, and the expression of OPN was analyzed with qPCR and ELISA
(n=4) (A–D). Primary osteoblasts were incubated with HGF for indicated time intervals, and Akt phosphorylation was examined by Western blotting
(E). Primary osteoblasts cells were pretreated with c-Met inhibitor and Ly294002 for 30 min or transfected with c-Met siRNA for 24 h followed by
stimulation with HGF for 30 min, and Akt phosphorylation was determined by Western blotting (F). *: p,0.05 as compared with HGF-treated group.
doi:10.1371/journal.pone.0038378.g003
HGF Induces OPN Expression
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5% CO2 at 37uC.
Measurement of OPN Production
Human osteoblasts were cultured in 24-well culture plates. After
reaching confluency, cells were treated with HGF and then
incubated in a humidified incubator at 37uC for 24 h. To examine
the downstream signaling pathways involved in HGF treatment,
cells were pretreated with various inhibitors for 30 min before
addition of HGF (30 ng/ml) administration. After incubation, the
medium was removed and stored at 280uC until the assay was
performed. OPN in the medium was assayed using OPN enzyme
immunoassay kits, according to the procedure described by the
manufacturer.
Quantitative Real Time PCR
Total RNA was extracted from osteoblasts by using a TRIzol
kit (MDBio Inc., Taipei, Taiwan). Two mg of total RNA was
reverse transcribed into cDNA by using oligo(dT) primer
[15,16]. The quantitative real time PCR (qPCR) analysis was
carried out using TaqmanH one-step PCR Master Mix (Applied
Biosystems, CA, USA). Two ml of total cDNA were added per
25-ml reaction with sequence-specific primers and TaqmanH
probes. Sequences for all target gene primers and probes were
purchased commercially (GAPDH was used as internal control)
(Applied Biosystems, Foster City, CA, USA). qPCR assays were
carried out in triplicate on an StepOnePlus sequence detection
system. The cycling conditions were 10-min polymerase
activation at 95uC followed by 40 cycles at 95uC for 15 s
and 60uC for 60 s. The threshold was set above the non-
template control background and within the linear phase of
target gene amplification to calculate the cycle number at which
the transcript was detected (denoted CT).
Western Blot Analysis
Cellular lysates were prepared as described [17,18]. Proteins
were resolved using SDS-PAGE and transferred to Immobilon
polyvinyldifluoride membranes. The membranes were blocked
with 4% BSA for 1 h at room temperature and then probed with
rabbit antibodies against human p-p85, p85, p-Akt, Akt, p-c-Jun,
or c-Jun (1:1000) for 1 h at room temperature. After three
washes, the blots were incubated with a donkey anti-rabbit
peroxidase-conjugated secondary antibody (1:1000) for 1 h at
room temperature. The blots were visualized with enhanced
chemiluminescence on Kodak X-OMAT LS film (Eastman
Kodak, Rochester, NY).
Kinase Activity Assay
c-Src activity was assessed by c-Src Kinase Activity Assay Kit
(Abnova, Taipei, Taiwan) according to manufacturer’s instruc-
tions. Kinase activity kit is based on a solid-phase ELISA that
uses a specific synthetic peptide as a substrate for c-Src and
a polyclonal antibody that recognized the phosphorylated form
of the substrate.
Transfection and Reporter Gene Assay
Human osteoblasts were co-transfected with 0.8 mg AP-1
luciferase plasmid and 0.4 mg b-galactosidase expression vector.
Cells were grown to 80% confluency in 12-well plates and then
transfected on the following day with Lipofectamine 2000
(LF2000; Invitrogen). DNA and LF2000 were premixed for
20 min and then added to the cells. After 24 h of transfection, the
cells were incubated with the indicated reagents. After a further
24 h of incubation, the medium was removed, and cells were
washed once with cold PBS. To prepare lysates, 100 ml reporter
lysis buffer (Promega, Madison, WI) was added to each well, and
cells were scraped from dishes. The supernatant was collected after
centrifugation at 13,000 rpm for 2 min. Aliquots of cell lysates
(20 ml) containing equal amounts of protein (20–30 mg) were
placed into wells of an opaque black 96-well microplate. An equal
volume of luciferase substrate was added to all samples, and
luminescence was measured in a microplate luminometer. The
value of luciferase activity was normalized to the transfection
efficiency, which was monitored by activity of the co-transfected b-
galactosidase expression vector.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation analysis was performed as
described previously [19]. DNA immunoprecipitated with an anti-
c-Jun Ab was purified and extracted with phenol-chloroform. The
purified DNA pellet was subjected to PCR. PCR products were
then resolved by 1.5% agarose gel electrophoresis and visualized
with UV light. The primers 59-TCT TCCTGG ATGCT-
GAATGC-39 and 59-CCA AGCCCT CCCAGA ATTTAA-39
were utilized to amplify across the OPN promoter region [20].
Statistics
The values given were means 6 S.E.M and analyzed with one-
way ANOVA. The difference was significant if the p value was
,0.05.
Results
HGF Induces OPN Production in Human Osteoblasts
HGF has been reported to stimulate proliferation and
differentiation of osteoblasts [13,14]. To examine the effects of
HGF on OPN expression, osteoblasts were exposed to HGF, and
the mRNA levels of OPN was determined. Treatment of
osteoblasts with HGF (3–30 ng/ml) for 24 h induced OPN
mRNA levels (Fig. 1A&B). In addition, stimulation of osteoblasts
with HGF also led to increased protein expression of OPN in
a concentration-dependent manner by using ELISA and Western
blotting (Fig. 1C–E). It has been reported that HGF exerts its
effects through interaction with a specific receptor c-Met [21].
Pretreatment of osteoblasts with c-Met inhibitor reduced HGF-
increased OPN expression (Fig. 1F–I). In addition, transfection of
cells with c-Met siRNA also reduced HGF-increased OPN
expression (Fig. 1F–I). Therefore, an interaction between HGF
and c-Met is very important for OPN production in human
osteoblasts.
Figure 4. c-Src is involved in HGF-mediated OPN production in osteoblasts. Cells were pretreated for 30 min with PP2 or transfected with
c-Src mutant and siRNA followed by stimulation with HGF for 24 h. Media and total RNA were collected, and the expression of OPN was analyzed with
qPCR and ELISA (n=5) (A–D). Primary osteoblasts were incubated with HGF for indicated time intervals, and c-Src phosphorylation was examined by
Western blotting (E). Primary osteoblasts were incubated with HGF for indicated time intervals, and c-Src kinase activity was examined by c-Src kinase
assay kit (F). Primary osteoblasts were pretreated with c-Met inhibitor, Ly294002, and Akt inhibitor for 30 min or transfected with c-Met and Akt siRNA
for 24 h followed by stimulation with HGF for 30 min, and c-Src kinase activity was examined by c-Src kinase assay kit (G). *: p,0.05 as compared with
basal level (F) or HGF-treated group (A-D&G).
doi:10.1371/journal.pone.0038378.g004
HGF Induces OPN Expression
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38378Figure 5. AP-1 is involved in the potentiation of OPN production by HGF. Cells were pretreated for 30 min with curcumin or transfected
with c-Jun siRNA followed by stimulation with HGF for 24 h. Media and total RNA were collected, and the expression of OPN was analyzed with qPCR
and ELISA (n=5) (A–D). Primary osteoblasts were incubated with HGF for indicated time intervals, and c-Jun phosphorylation was determined by
Western blotting (E). Primary osteoblasts were pretreated with c-Met inhibitor, Ly294002, Akt inhibitor, and PP2 or transfected with c-Met and Akt
siRNA, and then stimulated with HGF for 120 min. A chromatin immunoprecipitation assay was then performed. The chromatin was
immunoprecipitated with anti-c-Jun. One percent of the precipitated chromatin was assayed to verify equal loading (input) (F). MG63 cells were
pretreated with c-Met inhibitor, Ly294002, Akt inhibitor, or PP2, and then stimulated with HGF for 120 min, and c-Jun immunofluorescence staining
was examined (G). *: p,0.05 as compared with HGF-treated group.
doi:10.1371/journal.pone.0038378.g005
Figure 6. The c-Met, PI3K, Akt, and c-Src pathway is involved in HGF-induced AP-1 activation. (A&B) Primary osteoblasts were transfected
with the AP-1-luciferase expression vector and then pretreated with c-Met inhibitor, Ly294002, Akt inhibitor, and PP2 or cotransfected with c-Met and
c-Jun siRNA or p85, Akt and c-Src mutant before incubation with HGF for 24 h. Luciferase activity was then assayed (n=4). *: p,0.05 as compared
with HGF-treated group. (C) Schematic diagram of the signaling pathways involved in HGF-induced OPN expression in osteoblasts. HGF increases
OPN expression by binding to the c-Met receptor and activating PI3K, Akt, and c-Src, which enhances binding of c-Jun to the AP-1 site. This results in
the transactivation of OPN expression.
doi:10.1371/journal.pone.0038378.g006
HGF Induces OPN Expression
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the Potentiating Action of HGF
PI3K/Akt signaling pathway can be activated by a variety of
growth factors, such as insulin and HGF [22,23]. To determine
whether PI3K was involved in HGF triggered OPN expression,
osteoblasts were pretreated with Ly294002, a PI3K inhibitor for
30 min and then incubated with HGF for 24 h. As shown in
Fig. 2A–D, pretreatment with Ly294002 reduced HGF-induced
OPN expression. Transfection of cells with p85 mutant or siRNA
also reduced HGF-induced OPN expression (Fig. 2A–D). We then
directly measured p85 phosphorylation in response to HGF.
Stimulation of primary osteoblasts led to a significant increase in
phosphorylation of PI3K (Fig. 2E). In addition, treatment with c-
Met inhibitor or transfection with c-Met siRNA reduced HGF-
mediated p85 phosphorylation (Fig. 2F). Furthermore, pretreat-
ment of cells with Akt inhibitor or transfection with Akt mutant
and siRNA for 24 h markedly attenuated the HGF-induced OPN
production (Fig. 3A–D). Akt phosphorylation in response to HGF
was then measured. As shown in Fig. 3E, treatment of primary
osteoblasts with HGF resulted in a time-dependent phosphoryla-
tion of Akt. Pretreatment of cells with c-Met inhibitor and
Ly294002 or transfection with c-Met siRNA inhibited the HGF-
induced Akt phosphorylation (Fig. 3F). Taken together, these
results indicate that the PI3K and Akt pathways are involved in
HGF-induced OPN production.
c-Src is Involved in the HGF-mediated OPN Expression in
Osteoblasts
PI3K/Akt-dependent c-Src activation is involved in the
regulation of gene expression [24]. Therefore, we investigated
the role of Src in mediating HGF-induced OPN expression with
the specific Src inhibitor PP2. As shown in Figure 4A–D, HGF-
induced OPN expression was markedly attenuated by pretreat-
ment of cells for 30 min with PP2 or transfected of cells for 24 h
with c-Src mutant and siRNA. The major phosphorylation site of
c-Src at the Tyr
416 residue results in activation from c-Src
autophosphorylation [25]. To directly confirm the crucial role of
c-Src in OPN expression, we measured the level of c-Src
phosphorylation at Tyr
416 in response to HGF. As shown in
Figure 4E, treatment of primary osteoblasts with HGF resulted in
a time-dependent phosphorylation of c-Src at Tyr
416. In addition,
HGF also increased c-Src kinase activity (Fig. 4F). Pretreatment of
primary osteoblasts with c-Met inhibitor, Ly294002, and Akt
inhibitor or transfection with c-Met and Akt siRNA markedly
inhibited the HGF-induced c-Src kinase activity (Fig. 4G). Based
on these results, HGF appears to act through a signaling pathway
involving c-Met receptor, PI3K, Akt, and c-Src to enhance OPN
expression in human osteoblasts.
Involvement of AP-1 in HGF-induced OPN Expression
The promoter region of human OPN contains AP-1 binding site
[20]. To examine the role of the AP-1 binding site in HGF-
mediated OPN expression, the AP-1 inhibitor curcumin was used.
Pretreatment of cells with curcumin reduced HGF-enhanced OPN
expression (Fig. 5A–D). AP-1 activation was further evaluated by
analyzing the phosphorylation of c-Jun as well as by a chromatin
immunoprecipitation assay. Treatment of primary osteoblasts with
HGF increased c-Jun phosphorylation (Fig. 5E). In addition,
transfection of cells with c-Jun siRNA suppressed HGF-induced
OPN expression (Fig. 5A–D). We next investigated whether c-Jun
binds to the AP-1 element on the OPN promoter after HGF
stimulation. The in vivo recruitment of c-Jun to the OPN promoter
was assessed via chromatin immunoprecipitation assay. In vivo
binding of c-Jun to the AP-1 element of the OPN promoter
occurred after HGF stimulation (Fig. 5F). The binding of c-Jun to
the AP-1 element by HGF was attenuated by c-Met inhibitor,
Ly294002, Akt inhibitor, and PP2 or c-Met and Akt siRNA
(Fig. 5F). In addition, pretreatment of cells with c-Met inhibitor,
Ly294002, Akt inhibitor, and PP2 also reduced HGF-induced
accumulation of c-Jun into the nucleus (Fig. 5G).
To further confirm that the AP-1 element is involved in HGF-
induced OPN expression, we performed transient transfection
with AP-1 promoter-luciferase constructs. Primary osteoblasts
incubated with HGF showed a 3.2-fold increase in AP-1 promoter
activity. The increase in AP-1 activity by HGF was antagonized by
c-Met inhibitor, Ly294002, Akt inhibitor, and PP2 or c-Met and c-
Jun siRNA or p85, Akt, and c-Src mutant (Fig. 6A&B). Taken
together, these data suggest that the activation of the c-Met, PI3K,
Akt, c-Src, c-Jun, and AP-1 pathway is required for the HGF-
induced increase in OPN expression in human osteoblasts.
Discussion
In this study with osteoblasts, elevation of OPN mRNA and
protein levels followed recombinant HGF protein treatment
through c-Met receptor induction of the PI3K, Akt, and c-Src
signaling pathway. Our findings provide the first evidence that
HGF increased OPN expression, providing a link and molecular
mechanism between HGF family and OPN in the physiology of
bone. In this study, we provided the data from primary osteoblasts
to examine the molecular mechanism between HGF and OPN.
However, the interactions of these two molecules in the in vivo
scenario are large unknown. In next steps, we try to establish the
HGF knockout mice and to examine the OPN expression in the
bone. These data will provide the in vivo data of present study.
HGF plays an essential role in the development and re-
generation of the liver and also stimulates the growth, motility, and
morphogenesis of a variety of cell types [26]. Although initially
thought to be of mesodermal origin, HGF is expressed almost
ubiquitously, including by osteoblasts [27]. It has been postulated
to participate in bone remodeling and formation [13]. Previously
reported that HGF (10 ng/ml) combined with vitamin D3 may
have an autocrine and/or paracrine effect on the osteogenic
maturation, as well as on bone repair and remodeling [14]. In this
study, we found that high concentration of HGF (30 ng/ml)
induced osteogenic gene (OPN) expression. These data imply that
using high concentration HGF may increases osteogenic matura-
tion without vitamin D3 application. However, this hypothesis is
needs further examination. The biological activity of HGF is
mediated by binding to cell surface c-Met receptor. Here, we
confirmed that c-Met receptor is required for HGF-induced OPN
expression. Pretreatment of cells with c-Met inhibitor reduced
HGF-induced OPN expression. This was further confirmed by the
result that the c-Met siRNA inhibited the enhancement of OPN
production by HGF. Therefore, the interaction between HGF and
c-Met is very important for OPN production by human
osteoblasts.
PI3K/Akt have been characterized at the molecular level and
have been found to mediate several cellular molecular responses
[28]. Phosphorylation of the p85 subunit is required for activation
of the p110 catalytic subunit of PI3K [29]. We found HGF-
enhanced the p85 subunit phosphorylation in human osteoblasts.
Pretreatment of cells with PI3K inhibitor Ly294002 antagonized
an increase in OPN expression by HGF stimulation. This was
further confirmed by the result that the dominant-negative mutant
and siRNA of p85 inhibited the enhancement of OPN by HGF.
Moreover, we also found that HGF activated Akt Ser
473
HGF Induces OPN Expression
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inhibited HGF-mediated OPN expression. Our data indicates that
PI3K/Akt could play an important role in the expression of OPN
in human osteoblasts.
Src, a tyrosin kinase, plays a critical role in the induction of gene
transcription [30]. Because c-Src is a downstream effector of
PI3K/Akt [24], we examined the potential role of c-Src in the
signaling pathway HGF-induced OPN expression. Treatment of
cells with c-Src inhibitor PP2 or transfection of cells with c-Src
mutant and siRNA reduced HGF-mediated OPN expression. In
addition, we also found that treatment of osteoblasts with HGF
induced increases in c-Src phosphorylation and kinase activity.
These effects were inhibited by c-Met inhibitor, Ly294002, and
Akt inhibitor, indicating the involvement of PI3K/Akt-dependent
c-Src activation in HGF-mediated OPN induction.
There are several binding sites for a number of transcription
factors including NF-kB, Sp-1, and AP-1 in the 59 region of the
OPN gene [20]. Recent studies of the OPN promoter have
demonstrated that OPN induction by several transcription factors
occurs in a highly stimulus-specific or cell-specific manner [31,32].
The results of our current study show that AP-1 activation
contributes to HGF-induced OPN expression in osteoblasts.
Pretreatment of cells with an AP-1 inhibitor curcumin reduced
HGF-increased OPN expression. Therefore, the AP-1 binding site
is likely to be the most important site for HGF-induced OPN
production. The AP-1 sequence binds to members of the Jun and
Fos families of transcription factors. These nuclear proteins
interact with the AP-1 site as Jun homodimers or Jun-Fos
heterodimers formed by protein dimerization through their
leucine zipper motifs. The results of our study show that HGF
induced c-Jun phosphorylation. In addition, c-Jun siRNA abol-
ished HGF-induced OPN expression in osteoblasts. Therefore, c-
Jun activation mediates by HGF-increased OPN expression.
Furthermore, HGF increased the binding of c-Jun to the AP-1
element within the OPN promoter, as shown by a chromatin
immunoprecipitation assay. Binding of c-Jun to the AP-1 element
was attenuated by c-Met inhibitor, Ly294002, Akt inhibitor, and
PP2. Using transient transfection with AP-1-luciferase as an
indicator of AP-1 activity, we also found that HGF induced an
increase in AP-1 activity. In addition, c-Met inhibitor, Ly294002,
Akt inhibitor, and PP2 or c-Met and c-Jun siRNA or p85, Akt, and
c-Src mutant reduced HGF-increased AP-1 promoter activity.
These results indicate that HGF may act through the c-Met
receptor, PI3K, Akt, c-Src, c-Jun, and AP-1 pathway to induce
OPN production in human osteoblasts.
In conclusion, we explored the signaling pathway involved in
HGF-induced OPN expression in human osteoblasts. We found
that HGF increased OPN expression by binding to the c-Met
receptor and activating PI3K, Akt and c-Src, which enhanced
binding of c-Jun to the AP-1 site and resulted in the transactivation
of OPN expression (Fig. 6C).
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